BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO Sells $830,350.14 in Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 3,174 shares of the stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $261.61, for a total transaction of $830,350.14. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

John Oyler also recently made the following trade(s):

• On Tuesday, June 17th, John Oyler sold 1,460 shares of BeOne Medicines stock. The stock was sold at an average price of $256.49, for a total transaction of $374,475.40.
• On Monday, June 16th, John Oyler sold 3,680 shares of BeOne Medicines stock. The shares were sold at an average price of $266.05, for a total value of $979,064.00.
• On Friday, June 6th, John Oyler sold 5,127 shares of BeOne Medicines stock. The stock was sold at an average price of $252.77, for a total value of $1,295,951.79.

BeOne Medicines Stock Performance

Shares of NASDAQ ONC traded up $0.33 during midday trading on Wednesday, hitting $267.13. 292,986 shares of the company's stock traded hands, compared to its average volume of 444,749. The company has a fifty day moving average price of $246.44. BeOne Medicines Ltd. - Sponsored ADR has a 1 year low of $141.31 and a 1 year high of $287.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71. The stock has a market capitalization of $29.28 billion, a PE ratio of -71.81 and a beta of 0.30.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $1.93. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. On average, equities analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on ONC shares. Wall Street Zen upgraded BeOne Medicines from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Macquarie raised their price target on shares of BeOne Medicines from $259.00 to $313.00 and gave the company an "outperform" rating in a report on Friday, February 28th. JMP Securities set a $348.00 price target on shares of BeOne Medicines in a research note on Friday, February 28th. TD Securities restated a "buy" rating and set a $334.00 price objective on shares of BeOne Medicines in a research report on Thursday, April 24th. Finally, Royal Bank Of Canada dropped their target price on shares of BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $319.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.